CONNECT MIOT
Past events at MIOT
MIOT’s PCR NAT: Making Blood Transfusions Safer than Ever!
Consistently at the forefront of cutting-edge technology, MIOT has introduced state-of-the-art Polymerase Chain Reaction Nucleic Acid Testing (PCR NAT) for blood screening.
Blood safety is a challenge in India because of the high prevalence of Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), and Hepatitis B Virus (HBV) among the general population and thereby voluntary blood donors. Conventional antibody-detecting (serology) tests, though widely used, have limitations in accurately detecting viral infections. This may potentially increase the risk of undetected viruses being transmitted during blood transfusions. To ensure that blood transfusions are 100% safe, it is crucial to adopt innovative diagnostic methods to protect patient health.
PCR NAT: Ensuring 100% Safe Blood Transfusions
Consistently at the forefront of medical innovation, MIOT has introduced state-of-the-art Polymerase Chain Reaction – Nucleic Acid Testing (PCR NAT) for blood screening.
PCR NAT is a highly advanced diagnostic method that accurately detects life-threatening viruses in the blood. By identifying infections at an early stage, PCR NAT ensures that blood, plasma, and serum transfusions are 100% safe.
Challenging Window Period
The time interval between virus exposure and the production of detectable antibodies is known as the window period. During this period, if an infected person donates blood, conventional serological tests may fail to detect the infection, leading to the transmission of undetected infections to recipients. Additionally, conventional serological tests have a long window period, increasing the risk of disease transmission.
How PCR NAT Shortens the Window Period?
With high sensitivity, PCR NAT detects the infections within just a few days of exposure. This significantly shortens the window period, ensuring the safest blood for transfusion.
Infection |
Conventional serological test – Detects virus in |
PCR NAT – Detects virus in |
|---|---|---|
| HIV | 23 – 90 days | 8 – 11 days |
| HCV | 7 – 14 days | 3 – 5 days |
| HBV | 30 – 180 days | 15 – 20 days |
Benefits:
- Ensures safe blood / plasma / serum transfusions and organ transplantation
- Eliminates undetected transmission of life-threatening infections
- Highly sensitive and accurate
- Detects viruses at an early stage
- Fast turnaround time
- Quantifies viral load in real-time
- Complete automation reduces the chances of human error
After the virus exposure, the body takes several days to weeks to produce detectable antibodies against the virus. The tests to identify a virus’s genetic material are considered a significant technological advancement. They represent an additional step in our quest to achieve the goal of zero risk for blood transfusion recipients. By integrating advanced PCR NAT technology, MIOT International ensures unparalleled accuracy in detecting infections at their earliest stages, minimising the risk of transmission through blood transfusions. Unlike conventional methods that rely on antibody detection, PCR NAT identifies the virus at the genetic level, significantly shortening the window period and enhancing diagnostic precision.
This cutting-edge approach not only strengthens blood safety protocols but also enhances overall patient care. By enabling early detection, physicians can initiate timely treatment, reducing complications and improving recovery outcomes. For patients requiring blood transfusions or organ transplants, the reliability of PCR NAT ensures they receive the safest possible medical interventions.
This groundbreaking advancement reflects MIOT’s unwavering dedication to healthcare excellence, setting a new benchmark in both diagnostic accuracy and patient safety. Through continuous innovation, MIOT reaffirms its mission of enhancing patient care.